Filters
ACM publishes 'State of the Market 2026' report
Developments in the FSR: new guidelines and an investigation in the wind industry
The potential acquisition of Solvinity by a U.S. entity: risks to national security?
The withdrawal button: a win for consumers, a challenge for businesses
CJEU Ruling Reshapes Poland’s Pharmacy Advertising Rules
A European Perspective #1 | POLAND | The CJEU has found Poland’s prohibition on pharmacy advertising incompatible with EU law, effectively rendering the current provision unenforceable. Companies should monitor upcoming legislative changes and reassess promotional strategies in the interim.
9 of 9 Insights
No claim for damages as a result of participation in clinical drug trials
A European Perspective #1 | GERMANY | The Frankfurt am Main Regional Court confirms: No reduction in the burden of proof (presumption of causality) pursuant to Section 84 (2) of the German Medicines Act (AMG) for IMP (not even by analogy) and no liability on the part of the sponsor in the event of (insufficient) risk information provided by the investigating physician.
7 of 9 Insights
Ban on “social egg freezing” declared unconstitutional
A European Perspective #1 | AUSTRIA | The Austrian Constitutional Court holds that preventive egg retrieval without medical indication falls within the protection of Article 8 ECHR. A blanket prohibition is disproportionate; the legislature must introduce a new regulatory framework by 31 March 2027.
5 of 9 Insights
Promotional activities for medical devices may qualify as agency even without direct negotiation power
A European Perspective #1 | FRANCE | The French Supreme Court confirms a broad interpretation of commercial agent status. A key ruling increasing requalification risks and potential termination indemnity exposure for manufacturers and distributors.
6 of 9 Insights
Request for a Preliminary Ruling by Federal Court of Justice on the Prohibition of Advertising for Remote Medical Treatments under Section 9 HWG
Carbon Border Adjustment Mechanism (CBAM): From Reporting to Real Financial Impact
AI Act and Digital Omnibus Integration of AI and health data 2026
A European Perspective #1 | 2026 will be an integration year for AI in the healthcare sector. The AI Act will enter its implementation phase, while the Digital Omnibus introduces targeted simplifications. For life sciences companies, this means structurally aligning AI governance, data protection and product regulation.
3 of 9 Insights
Prediction Markets in Germany and Europe: Legal Status, Risks, and Opportunities